GlassScriptPhysician profile
Wentworth Jarrett
NPI 1104836972
$11,461.41
in general payments reported to CMS, 2019-2025
41 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,798 · 2020: $1,683 · 2021: $1,262 · 2022: $837 · 2023: $1,252 · 2024: $1,780 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,681 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,680.79 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,656.58 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,552.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $1,395.20 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $1,033.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.91 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $579.81 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $480.62 | 2019-2021 | |
| Glaxosmithkline, LLC. | $478.12 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $476.89 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $375.59 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $331.83 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Exact Sciences Corporation | $234.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Edwards Lifesciences Corporation | $212.89 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.96 | 2019-2022 | |
| Abbott Laboratories | $205.14 | 2019-2025 | Freestyle Libre 3 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wentworth Jarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.